Biopharma Deal Structuring: Anatomy of How Deals Get Built

A biopharma deal has five structural pillars, and the way they interact determines the transaction's true economics.

Upfront Payment. This is the non-contingent consideration paid at signing or close. It is the seller's floor — the guaranteed return from the transaction. Across our database, upfront payments represent a median of 15-22% of total deal value for Phase 2 assets and 25-35% for Phase 3 assets. The upfront ratio is the most reliable signal of buyer conviction: a high ratio means the buyer sees limited remaining risk; a low ratio means the buyer is hedging through contingent payments.

Milestone Payments. Development milestones (IND filing, first patient dosed, Phase 2/3 initiation, data readout), regulatory milestones (NDA/BLA submission, FDA/EMA approval, additional territory approvals), and commercial milestones (first commercial sale, revenue thresholds) form the staircase of contingent payments. The total milestone package — the biobucks — is the number that appears in press releases and is the number most commonly misinterpreted. Our data shows that the median achievability across all milestone types is approximately 38%. Commercial milestones above $1B in net sales achieve at less than 20%.

Royalties. The ongoing percentage of net sales paid by the licensee. Royalty rates typically range from 5-8% for preclinical assets to 12-20% for Phase 3 assets, with tiered structures that increase the rate as sales cross specified thresholds. Royalties represent the longest-duration economic interest in the deal and are often the most valuable component for a blockbuster drug — a 12% royalty on a $3B peak-sales drug generates $360M annually, dwarfing any milestone payment.

Territory and Field Rights. How geographic and indication rights are carved determines the licensor's retained optionality. A global, all-indications license maximizes upfront proceeds but eliminates the licensor's ability to capture value from additional partnerships. Territory splits — US/ex-US, US/ex-China/China — allow the licensor to run parallel partnerships and are increasingly common: approximately 35% of deals in our database since 2024 involve some form of territorial split.

Contingent Value Rights (CVRs) and Earnouts. In M&A transactions, CVRs and earnouts bridge the valuation gap when buyer and seller cannot agree on the probability of a future event. CVRs are typically tied to clinical or regulatory milestones, earnouts to financial performance. Across our dataset, CVR components represent a median of 20-25% of total consideration when present, and achieve at approximately 35-40%. See our dedicated CVR guide for a deeper analysis.

These five components are interdependent. A higher upfront allows the seller to accept lower milestones. A broader territory grant commands a higher royalty rate. A CVR on a late-stage asset may substitute for milestones that would otherwise be negotiated individually. The art of deal structuring is understanding these trade-offs and optimizing across all five dimensions simultaneously.

The first mistake is optimizing for headline total deal value. The press release number — "$2.1B licensing deal" — tells you almost nothing about the transaction's economic value. What matters is the probability-weighted present value, which requires knowing the upfront amount, the milestone trigger events and their probabilities, the royalty rate and its step-down provisions, and the time value of each payment. Companies that chase large biobucks numbers consistently accept worse economic outcomes than those that negotiate for achievable near-term value.

The second mistake is treating deal structure as fixed. Term sheets often present a structure — upfront, milestones, royalties — as though each component were independently determined. In practice, structure is a system of trade-offs. A company willing to accept a lower upfront can negotiate higher royalties. A company willing to grant broader territory can negotiate milestone acceleration. Understanding these trade-offs — and knowing which components the counterparty values most — creates room for value creation that does not appear in the initial offer.

The third mistake is ignoring the counterparty's internal constraints. Large pharma companies have capital allocation processes, quarterly earnings sensitivities, and accounting treatment preferences that shape their structural flexibility. A buyer who cannot load a large upfront into a single quarter may be willing to pay more in aggregate if the structure includes a signing payment and a deferred payment 90 days later. Understanding these constraints is not gamesmanship — it is the basis for structures that work for both parties.

The fourth mistake is failing to benchmark against comparable transactions. Negotiating a deal structure without knowing what comparable assets have transacted for is like negotiating a salary without knowing the market range. Companies that enter negotiations with comp-based benchmarks — from platforms like Solidus — negotiate from objective data rather than subjective conviction. The result is materially better outcomes on every structural dimension.

The fifth mistake is undervaluing retained rights. Every right not granted in a licensing deal — reserved territories, retained indications, manufacturing rights — has economic value. Companies that grant global, all-indication rights to a single licensee capture maximum immediate value but eliminate the optionality to license retained rights to additional partners, pursue independent development in retained territories, or negotiate improved terms in a subsequent transaction for the retained rights. The retained-rights strategy should be as carefully designed as the licensed-rights economics.